Q2 2026 Devyser Diagnostics AB Earnings Call Transcript
Key Points
- Devyser Diagnostics AB (STU:OL0) achieved positive EBIT for the fifth consecutive quarter, demonstrating effective cost control.
- The company finalized the acquisition of CyberGene, which is expected to enhance its market position.
- A new version of the Chimerism product was launched, strengthening competitive positioning and aiding Thermo Scientific in acquiring more accounts.
- Direct sales in the US showed strong development, particularly in hereditary products, with several regions experiencing over 30% growth.
- The company secured a loan agreement with SEB, providing strategic flexibility and a financial buffer for future opportunities.
- Sales in the second quarter were negatively impacted by lower than expected orders from the largest distributor, leading to an 11% decline in revenue compared to the previous year.
- The transplant product segment experienced weak sales due to delayed lab onboarding and volume buildup.
- Gross margin was affected by a one-off inventory impact, reducing it to 76% for the quarter, below the target of 80%.
- The company anticipates a weaker second half of the year, particularly in distributor sales, with a return to growth not expected until 2027.
- The inventory adjustment came as a surprise, indicating potential challenges in forecasting and managing distributor relationships.
Welcome to Devyser Diagnostics Q2 Report 2026 presentation. (Operator Instructions)
Now, I will hand the conference over to the speakers, CEO, Jan Wahlstrom and CFO, Sabina Berlin. Please go ahead.
Good morning, welcome to Devyserâs Q2 2026 earnings call. Iâm Jan Wahlström, CEO of Devyser, and would like to thank you everyone for joining our call today. On the call today, we have, in addition to myself, also our CFO, Sabina Berlin. I will start with a short summary of highlights for the quarter before handing over to Sabina for a more detailed review of our financial results for April to June.
Weâll go through an update on our recent commercial activities. Second quarter had a setback in sales due to lower than expected sales to our biggest distributor. However, despite this, we had positive EBIT earning for the fifth consecutive quarter and for the first half year, improved profitability when we had flat sales.
In the second quarter of the year, we had weak sales in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
